Schering Negotiating 150 Drug Contracts With Part D Plans
Executive Summary
Schering-Plough will finish negotiations on more than 150 contracts with prospective Medicare prescription drug plans (PDPs) over the summer
You may also be interested in...
Pfizer Medicare Part D Formulary Placement: Bundled Up, Or Out In The Cold?
Pfizer appears to have taken an all-or-nothing approach to negotiating formulary positioning for its products in Medicare Part D prescription drug plans, according to an analysis by "The Pink Sheet" of plan formularies
Pfizer Medicare Part D Formulary Placement: Bundled Up, Or Out In The Cold?
Pfizer appears to have taken an all-or-nothing approach to negotiating formulary positioning for its products in Medicare Part D prescription drug plans, according to an analysis by "The Pink Sheet" of plan formularies
Medicare Aranesp Reimbursement Drops “Equitable Adjustment” To Procrit
Medicare will no longer consider Amgen's Aranesp to be "functionally equivalent" to Johnson & Johnson's Procrit when reimbursing hospitals for outpatient use of the biological product